(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 7.51% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.64%.
Amneal Pharmaceuticals's revenue in 2026 is $3,195,719,000.On average, 10 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,140,354,852,198, with the lowest AMRX revenue forecast at $1,076,595,323,340, and the highest AMRX revenue forecast at $1,184,603,268,400. On average, 10 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,248,362,797,258, with the lowest AMRX revenue forecast at $1,154,988,186,690, and the highest AMRX revenue forecast at $1,342,782,646,004.
In 2028, AMRX is forecast to generate $1,389,469,951,288 in revenue, with the lowest revenue forecast at $1,230,942,160,958 and the highest revenue forecast at $1,496,432,658,170.